Figure 5.

Manipulating the IDO pathway reinforces therapeutic responses to DNP treatments. (A) The kynurenine pathway. (B,C) B6 (WT) mice were treated with DNPs or Vh (glucose 5%), as described previously. Other groups received DNPs and drugs that inhibit KatII (B; PF-04859989 daily from day 11–22, 40 mg/kg, i/p), or HAAO (C; 4-chloro-3-hydroxyanthranilic acid daily from day 11–21, 125 mg/kg, i/p). Mice were monitored and EAE clinical scores were recorded. Data were analyzed by two-way ANOVA. Experiments were repeated once (n = 8–10). NS, not significant; *p < 0.05; **p < 0.01; #p < 0.0001.